Australia markets open in 5 hours 24 minutes

Pyxis Oncology, Inc. (PYXS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.9600-0.2400 (-7.50%)
As of 02:34PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 188.44M
Enterprise value 52.20M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)8.70
Price/book (mrq)1.02
Enterprise value/revenue 3.23
Enterprise value/EBITDA 1.09

Trading information

Stock price history

Beta (5Y monthly) 1.34
52-week change 326.23%
S&P500 52-week change 323.12%
52-week high 36.8500
52-week low 31.3500
50-day moving average 33.9347
200-day moving average 33.2769

Share statistics

Avg vol (3-month) 3577.54k
Avg vol (10-day) 31.25M
Shares outstanding 558.89M
Implied shares outstanding 658.89M
Float 839.2M
% held by insiders 119.85%
% held by institutions 146.44%
Shares short (14 June 2024) 42.31M
Short ratio (14 June 2024) 46.42
Short % of float (14 June 2024) 44.91%
Short % of shares outstanding (14 June 2024) 43.92%
Shares short (prior month 15 May 2024) 41.96M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-29.77%

Management effectiveness

Return on assets (ttm)-19.95%
Return on equity (ttm)-34.37%

Income statement

Revenue (ttm)16.15M
Revenue per share (ttm)0.37
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -61.46M
Net income avi to common (ttm)-57.8M
Diluted EPS (ttm)-1.3700
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)157.03M
Total cash per share (mrq)2.67
Total debt (mrq)20.78M
Total debt/equity (mrq)11.28%
Current ratio (mrq)12.19
Book value per share (mrq)3.13

Cash flow statement

Operating cash flow (ttm)-64.58M
Levered free cash flow (ttm)-29.3M